Kings Park Slope, Inc., Brooklyn, NY

Is Kings Park Slope, Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “De-registered as an Outsourcing Facility”.

Does Kings Park Slope, Inc. hold a New York pharmacy license?

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054015485 for KINGS PARK SLOPE LLC, BROOKLYN, NY, status CHANGE OF OWNERSHIP, as of Nov 13, 2026.

Has Kings Park Slope, Inc. had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Nov 15, 2019), 1 state referral letter (Nov 15, 2019) and 1 FMD-145 letter (Nov 15, 2019) for Kings Park Slope, Inc. State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026. The state referral and handoff letters above are FDA’s letters to the state, not board actions.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Kings Park Slope, Inc.
Location
Brooklyn, NY
Type as FDA labels it
503A
FDA’s note
De-registered as an Outsourcing Facility
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Nov 15, 2019
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 17 observations
State board records
Not checked (license records); board actions matched: 0

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Kings Park Slope, Inc., a 503A facility, with 3 dated actions.

Document
Nov 15, 2019State referral letterReferral Letter to the New York State Board of Pharmacy Issued 11/15/2019FDA copy (archived)
Nov 15, 2019FMD-145 letterFMD-145 Issued 11/15/2019FDA copy (archived)
Nov 15, 2019Warning letter close-outWarning Letter Closeout (11/15/2019)fda.gov

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Kings Park Slope Inc, Brooklyn, NY (FEI number 3007174596), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Sep 14, 2018Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30071745961065569
Mar 14, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3007174596868804

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 17 numbered observations in all, across 2 inspections ending Jul 11, 2015 to Apr 22, 2016. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Apr 4, 2016 to Apr 22, 2016: 9 observations

Firm on the cover
Kings Park Slope, Inc., 357 Flatbush Ave, CODE
FEI number
3007174596
FDA district office on the cover
158-15 Liberty Avenue, Ja maica, NY 11433
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions. S pecifically,

(a) Positive pressure differential was lost in the ISO redacted b4 cleanroom on 1/5/2016, 1/6/2016 , 1/7/2016, 1/10/2016, 1/11/2016, and 1/31/2016 and in the ISO 8 anteroom on 12/6/2015, 1/2/2016, 1/5 /2016, 1/9/2016, and 1/10/2016. Since the firm does not have continuous monitoring of pressure diff erential in place and only records the pressure differential redacted b4 it is unknown whether the loss of pos itive pressure occurred during sterile processing. (b) The firm failed to conduct passive viable air sampling using settling plates when compounding operations are occurring as per SOP 03-18.01, entitled, redacted b4 Passive Viable Air Samplin g." On 4/5/2016, we observed the compounding/filling of Glycopyrrolate 0.6 mg/3 mL in 6 mL syringe (Lot #004051 61; Used By 05/20/201 6). We were informed by the firm that viable air sampling is performed only redacted b4 by an outside contractor redacted b4. . ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include adequate validation of the sterilization process. Specifically,

(a) Media fill simulation has not been performed for all aseptic processing. Management stated media fill was only performed redacted b4. <o (4 (b) Per SOP 05-04.0l, entitled, "Hand Hygiene and Sterile Garbing Procedure," "Protective eye wear will be redacted b4. Management indicated goggles may be redacted b4. There is no assurance that sterility of the goggle can be maintained during de-gowning.

(b) Per SOP 05-04.0l, entitled, "Hand Hygiene and Sterile Garbing Procedure," "Protective eye wear will be redacted b4. Management indicated goggles may be redacted b4. There is no assurance that sterility of the goggle can be maintained during de-gowning.

(b) Per SOP 05-04.0l, entitled, "Hand Hygiene and Sterile Garbing Procedure," "Protective eye wear will be redacted b4. Management indicated goggles may be redacted b4. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Written records are not made of investigations into unexplained discrepancies. Specifically,

(a) No investigation was initiated for loss of. positive pressure differential in the ISO 7 re da cted b4 c leanroom on 1/5/2016, 1/6/2016, 1/7/2016, 1/10/2016, 1/11/2016, and 1/31/2016 and in the ISO 8 anteroom on 12/6/2015, 1/2/2016, 1/5/2016, 1/9/2016, and 1/10/2016.

(b) The firm has no written procedure which addresses actions to be taken in the event of action or alert limit

excursions for environmental and personnel monitoring. On the first day of the inspection, the FDA inspection team observed the reading of redacted b4 plates and it was found a plate from the monitoring of a component tote employed in the anteroom exhibited a visual result of too numerous to count. In response to our query, management stated that the redacted b4.

Observation 4

The separate or defined areas necessary to prevent contamination or mix-ups are deficient. Specifically,

On 04/05/2016, during our observation of the technician gowning in the ante room, we saw redacted b6, b7c sleeve touched a cart and the top of redacted b6, b7c hood touched shelving on the other side. The placement of a cart in the ante room appeared to reduce the space for redacted b6, b7c to conduct gowning.

Observation 5

Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product. Specifically,

Preservative content (relative concentration) have not been tested and confined for the following lots of Pr ogesterone in Olive Oil 50 mg/mL IM: P01141550 (prepared on 01/14/2015), P05271550 (prepared on 05 /27/20 15), P09081550 (prepared on 09/08/20 15), and P12171550 (prepared on 12/17/2015) .

Observation 6

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment

Sporicidal disinfection of aseptic manufacturing areas is only performed redacted b4.

Observation 7

Employees are not given training in written procedures required by current good manufacturing practice re gulations. Specifically,

The firm has a written procedure which addresses good documentation practices including the proper manner to handle correction of errors; however, in the course of reviewing monitoring logs for equipment employed in th

e laboratory, it was observed that there were a number entries which had been either crossed out and re-writte n without initials and date or were covered by white-out and rewritten without initials and date. Management stated that this is a new employee who had not been trained yet regarding good documentation practices and, in fact, had not received any CGMP training despite the fact that he was given documentation responsibilities.

Brooklyn, NY 11238

503B O utsourcing Facility

Observation 8

The labels of your outsourcing facility's drug products do not include information required by section 503B (a)(10) ( A) and (B). S pecifically,

• The statements, "This is a compounded drug," and "Not for Resale," as well as the Jot or batch number; st

orage and handling instructions; and information to facilitate adverse event reporting www .fda.gov/medwatch and 1-800-FDA-1088, are not on your outsourcing facility' s drug product labels. Example s of drug product labels that do not contain this information:

o 20 Progesterone/Olive Oil 50 mg/mL o 30 Progesterone/Olive Oil 50 mg/mL o Total Parenteral Nutrition Solution Formula redacte d b4 1100 mL, Dextrose 70% 297 mL, Sterile Water for Injection 150 mL, with Additi ves: Sodium Chloride 25 mEq, Calcium G lucona te 5 mEq, Magnesium Sulfate 5 mEq, Potassium Chloride 37.6 mEq, Potassium Phosphate 12 m Mol, Sodium Acetate 40 mEq, and r edacted b4 10 mL • In addition to the above, the name, address, and phone number of your outsourcing facility is also not on your

outsourcing facility's drug product labels. E xamples of drug product labels that do not contain this i nformation: ...

Read the full 483 (PDF on fda.gov)

Observation 9

Your outsourcing facility did not submit a report to FDA identifying a product(s) compounded during the previous six months for the December 2015 reporting period as required by section 503B(b)(2)(A). Specifically, the toll owing are examples of products that were compounded between June 1, 2015, and November 30, 2015, but w ere not identified on your report dated December 21,2015:

• Irinotecan 250 mg/ 12.5 mL, Dextrose 5%262 mL compounded on 6/15/2015 for patient redacted b6 • Fludanibine Phosphate 57 mg/2.28 mL, Sodium Chloride 0.9% 105 mL compounded on 7/8/2015 for patient r

edacted b6

• Doxorubicin 108 mg/54 mL repackaged on 1011 3/2015 for patient redacted b6 • I Leuprolide Microdose compounded on 6/19/2015 for Rx redacted b6 • 15 Diazepam Vag Cream 2 mg/gm compounded on 11/28/2015 for Rx redacted b6

Inspection dated Jul 11, 2015 by FDA (dates on the form not read): 8 observations

Firm on the cover
Kings Park Slope Inc., 357 Flatbush Avenue CITY, STAT E AN D ZIP CODE --- ----------
FEI number
3007174596
Establishment type on the cover
Outsourcing Facility Brooklyn, NY 11238-4378
FDA district office on the cover
03/04-06 & 14/2014 158-15 Liberty Ave. Jamaica, NY 11433-1034
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Your firm failed to establish an adequate system for maintaining equipment used to control the aseptic conditions.

Specifically:

a.Smoke studies were not performed under dynamic conditions to verify that operators and processing equipment do not alter or impede the unidirectional cascade of air from the HEPA filters to the ISO 5 laminar flow benches wher e sterile drug products are opened and manipulated, and to the rest of the ISO 7 clean room.

b.Adequate exhaust systems or other systems to control contaminants are lacking in that:

1).The REDACTED (b)(4) wall mounted Magnehelic Pressure Gauges used for measuring the air pressures of the cle anroom and surrounding areas have not been calibrated. 2). One of the recirculating vents in the non-hazardous cleanroom was partially blocked by a printer.

Observation 2

Clothing of personnel engaged in the processing of drug products is not appropriate for the duties they perform.

Specifically, sterile drug products are aseptically manipulated by the cleanroom operators who wear non-sterile gowns above the knees, non-sterile pants, non-sterile glasses/goggles, non-sterile footwear and non-sterile facial masks. The only apparel that is sterile is the operator's gloves in the non-hazardous ISO 5 area. Non-sterile gloves are used at the hazardous chemo ISO 5 work area. The operator's face and head are not fully covered and allows exposed facial skin and hair over the critical ISO 5 laminar flow areas. Additionally, gowning apparel is composed of particle shedding material.

Observation 3

Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas.

Specifically, a. Environmental monitoring for viable air counts in the ISO 5 zones is not performed at least daily during periods of production. b. Environmental monitoring for non-viable particulates in the ISO 5 zones is not performed under dynamic conditions. c. The work surfaces, inside the ISO 5 hoods, are not tested for microbial contamination at least daily at the end of operations. d. Operators' gloves are not tested for microbial contamination at least daily.

Observation 4

Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

a. Non-sterile wipes are used to disinfect the ISO 5 hoods' sterile processing surfaces. b. The firm does not use sporicidal disinfectants to disinfect the ISO 5 surfaces.

Observation 5

Your firm does not have, for each batch of drug product purporting to be sterile and/or pyrogen-free, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product. Specifically, given the observed inadequate environmental controls, testing is deficient in that:

a. Sterility testing. Your firm only performed sterility testing in limited cases, for one product. b. Endotoxin testing. Data is not available for any sterile drug products produced.

Observation 6

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile do not include validation of the sterilization process.

No media fills/process simulations have been performed under the most stressful or challenging conditions.

Observation 7

Containers and closmes are not tested for conformance with all appropriate written procedures.

Specifically, the firm does not receive or review certificates of analysis showing sterility for the sterile containers and closures used to process sterile drug products.

Observation 8

Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and/or sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter th e safety, identity, strength, quality, or purity of the drug product beyond the official or other establishe d requirements.

Specifically, purchased sterile equipment, such as transfer tubing or ophthalmic drops containers, are accepted into inventory and used for sterile drug processing without reviewing the manufacturer's certificate of analysis to assure sterility.

Linked 483s whose text is not shown

State board of pharmacy records

State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.

What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054015485LICENSED PHARMACYKINGS PARK SLOPE LLCBROOKLYN, NYCHANGE OF OWNERSHIP

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.